The PennZone

  • Home
  • Business
  • Entertainment
  • Technology
  • Construction
  • Real Estate
  • Health
  • Non-profit
  • Travel

Beneficience.com Legacy PR Announces Dr. Burd Renowned Diabetes Scientist, Biochemist-entrepreneur and Dexcom Founder, client
The PennZone/10216335

Trending...
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • Bethany Nikitenko Elected Board Vice President of Philadelphia VIP
Beneficience Com Announces Dr John Burd, Renowned Dr John Burd Lysulin© Dr Burd Wonder Spray Skin Rescue 8oz Skin Rescue Lysulin© Products Beneficience.com Legacy PR
Dr. Burd is a renowned diabetes scientist and biochemist and Founder of Dexcom, the worldwide leader in Continuous Glucose Monitoring (CGM) systems. Get to know him and what good he is doing in the world, and for whom his life work benefits.

SAN DIEGO - PennZone -- About John Burd, PhD:

Dr. Burd is Founder & CEO of Lysulin, Inc and Wonder Spray, llc.  In 2017 Dr. Burd founded Lysulin, Inc, developing scientifically proven nutraceutical products to improve the health of people with diabetes.   The first patented product, Lysulin®, was launched in January 2018 and is showing remarkable results in clinical studies in lowering HbA1c and glycated proteins, the cause of disease complications.  In 2019 Dr. Burd founded Wonder Spray, llc to provide relief for a variety of ailments and skincare problems using a natural and safe chemical that is used by white blood cells to kill all pathogens.

Dr. Burd was previously President & CEO of DexCom, where he directed the company's work to develop, manufacture and market the first long-term implantable glucose sensor for people with diabetes.  In April 2005, DexCom completed a successful IPO, valuing the company at over $500 million.  In 2020 DexCom had a market cap of over $40 billion.  From 1999 to 2004 Dr. Burd was a General Partner of Windamere Venture Partners.

Before founding DexCom, Dr. Burd was the Founder, President, CEO and Chairman of LXN Corporation, which developed and marketed the Duetâ Diabetes Control System to healthcare professionals and the In ChargeÔ Diabetes Control System to the diabetes self-testing market.  LXN was sold to Johnson and Johnson in 2000.

More on The PennZone
  • Second Annual "Autism In Bloom" Event By D&D Journey Promotes Autism Awareness Month
  • PlanetAI Nature Space (PNS), certificadora Europea, lanza su plataforma EUDR-PNS Ready basada en IA, satélites y trazabilidad blockchain
  • Rhealize Strategic Talent Advisory Co-Founder Dona Baker to Speak at DisruptHR YEG 15.0 in Edmonton on Hiring Innovation
  • Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
  • Primo Sewer Cleaning Acquires Industry-Leading Hydro Jetter Mongoose Jetter Model 123

Previously, Dr. Burd held executive positions at QUIDEL Corporation, where he directed the development of enzyme immunoassay products for the clinical lab, physician's office and OTC markets. Prior to joining QUIDEL, Dr. Burd was Executive Vice President and COO for MAST Immunosystems, Inc. where he was responsible for the company's operations, including research and development, marketing, sales and finance.  MAST Immunosystems was purchased by Hitachi Chemical in 1997.  Previously, Dr. Burd was involved in other medical product research and development at Miles Laboratories, Inc. (now Bayer Corporation).

Dr. Burd has authored and co-authored over 45 articles and his work in the medical and biotechnology field has led to the filing and ownership of forty patents and the development of many innovative medical products.  He graduated from Purdue University with a B.S. in Biochemistry, and earned an M.S. and Ph.D., also in Biochemistry, from the University of Wisconsin.  In 2010 Dr. Burd was inducted into the American Association of Clinical Chemistry Hall of Fame and received the Ullman Prize for innovation in clinical chemistry.

Disclaimer: Dr. Burd's published product statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

JOHN F. BURD, Ph.D.

Founder & CEO Lysulin, Inc and Wonder Spray, llc.

More on The PennZone
  • UK Financial Ltd Confirms CATEX Exchange Integration of SMPRA and LTNS 1 Ahead of Compliance-Based Trading Activation
  • Best Companies Group Opens Free Registration for Best Credit Unions to Work For Program
  • Ashikaga Flower Park's "Great Wisteria Festival 2026"
  • Washington County PA Real Estate is Changing Here's What Homeowners Need to Know Before Selling
  • Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027

4930 Bradshaw Court, San Diego, CA  92130
Phone: 619-992-2873

Website: Promotes Healthy Insulin Function and helps maintain healthy A1c (lysulin.com)

Learn more about Dr. Burd's products below...

Insulin resistance: https://www.youtube.com/watch?v=rdiHqff3EY8



Lysulin video:  https://www.youtube.com/watch?v=PK3CkMty6RE



Running A1c test: https://tinyurl.com/y379jbla

Wonder Spray:
https://www.youtube.com/channel/UCYFv1jgn3LmADcZklzLbMHA/videos

Follow Burd's PR News at http://Beneficience.com

MEDIA REQUESTS + MEDIA BOOKING: Dr. Burd is available for relevant events, speaking engagements, radio, podcast, television and media opportunities, news interviews, et als. Burd's media contact information is available now by request online at Beneficience.com Legacy PR at https://beneficience.com/?s=Dr.+John+Burd

Contact
Dr. Tracey Bond, MPRL
Certified Publicist of Record
for John Burd, PhD
***@beneficience.com


Source: Beneficience.com Legacy PR
Filed Under: Business

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on The PennZone
  • Ocean County College Introduces Pathways to Simplify the Student Journey and Strengthen Career Connections
  • Kiko Nation Expands to Apple App Store, Achieving Full Mobile Deployment for Livestock Digital Registry Platform
  • The Lawyers' Marketer Launches Claude AI Implementation Service for Law Firms
  • Certified Trading Card Association and Collectors MD Launch Healthy Hobby Initiative
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • L2 Aviation Earns FAA STC for Thales AVIATOR 200S for Boeing 777
  • Pittsburgh-Based Phoinix Events Selected as Vendor for NFL Draft
  • FinIQ Edu Launches High-Impact Workshop Vertical to Close the Workplace Benefits Gap—Drives 82% Surge in 401(k) Participation Intent
  • HousingWire launches Mortgage Rankings, bringing a data-driven benchmark to originator performance
  • J&J Exterminating Reminds Residents to prepare for Termite Swarm Season
  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Tyler G. Hicks' Encyclopedia of Wealth Building Secrets Released in a Powerful New Edition
  • Just 1 in 57 Crypto Owners Globally Pay Taxes on Their Holdings, New Report Finds
  • New Book Gives Technology Leaders the Blueprint to Drive Real, Lasting Impact
  • IQSTEL accelerates toward profitability inflection with $317M revenue and AI-driven expansion; IQSTEL Inc. (N A S D A Q: IQST) i
  • AI-Driven Breakthrough Unleashed: Bionic Intelligence Platform Goes Live to Capture Massive Biotech Opportunity: KALA BIO, Inc. (N A S D A Q: KALA)
  • Surging Into Hyper-Growth Mode With Record Revenue, Raised 2026 Guidance, and Game-Changing AI Platform; Off The Hook YS (NYSE American: OTH)
  • Mom Creators Coalition Launches with WaterWipes® as Official Founding Sponsor
  • PandaGuarantee Launches Rent Guarantor Service in New York City
  • The $112M Marketing Lesson Joe Whyte Learned: Why 'More Traffic' Is the Biggest Lie in Digital Marketing

Popular on PennZone

  • Registered Nurse Launches Healthcare Wealth Strategy Practice for Healthcare Professionals
  • Actress/Model Raelia Lewis Building a Powerful Name in Entertainment and Fashion
  • New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
  • Conexwest: Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
  • Quadcode Acquires Significant Stake in Game 7, LLC - The Parent Company for FPFX Tech and PropAccount.com
  • Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
  • Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
  • New Report Reveals Surprising Trends in Ohio Airport Accidents
  • L-Tron Returns from a Successful PACK EXPO East Conference
  • Lawsuit Filed Against Boeing Over Defective Seat Switch on Boeing 787

Similar on PennZone

  • NAIDOC Week Australia 2026 | 50 Years Deadly - Celebrates Culture, Resilience, and Global Connection
  • Instant IP Teams: Bringing Enterprise-Grade Collaboration to IP Protection at the Speed of Thought
  • Architect of Neurodiversity Will Lead the First U.S. Team of Autistic Children to the "Genius Cup" in Hiroshima, Japan, in 2027
  • Deborah E. Jones Introduces Emotional Sovereignty, a Powerful New Book on Emotional Mastery, Resilience, and Intentional Living
  • Alchemy 43 Appoints Shane Smith as CEO to Drive Operational Performance and Scalable Growth
  • Best Spiritual Healing, Meditation & Retreats in Sedona — Rise Meditation Helps You Find and Book Transformational Experiences
  • $16 Billion Market by 2034 in Underwater Drones Presents Huge Opportunity for AI-Powered Autonomous Vehicle Serving Defense & Commercial Customers
  • Quality Water Treatment Unveils SoftPro Elite HE Water Softener for City Water, Setting a New Standard in Residential Water Treatment
  • Blue Sparrow Coffee named Best Matcha in Westword's Best of Denver 2026
  • L2 Aviation Earns FAA STC for Thales AVIATOR 200S for Boeing 777
Copyright © The PennZone | Theme: OMag by LilyTurf Themes
  • Contribute
  • Privacy Policy
  • Terms of Service
  • Contact Us